Serum procollagen type III peptide levels in patients with acute viral hepatitis

Giorgio Annoni, Maria Francesca Donato, Cristina Cantaluppi, Pietro Lampertico, Antonietta Cargnel, Paolo Viganò, Eckhart George Hahn, Massimo Colombo

Research output: Contribution to journalArticlepeer-review


Serum levels of procollagen type III peptide were measured by radioimmunoassay in 76 consecutive patients with acute viral hepatitis, in order to see if this index of hepatic fibrogenesis is also predictive for the development of chronic active hepatitis in high-risk patients. Serum procollagen levels were high (from 14.2 to 109.2 ng/ml, median 33.7 ng/ml) in 74 (97%) patients and normal (from 4 to 14 ng/ml, median 9.1 ng/ml) in 2 (3%) patients. The baseline serum procollagen levels were similar in all the subgroups of patients independently of the type of hepatitis. In the 59 patients with resolving hepatitis, serum procollagen levels returned to normal values from 2 to 48 weeks (mean 15). In the 17 patients with unresolved hepatitis, procollagen levels remained within the normal limits in 6 of 7 patients with non-progressive chronic disease, while were elevated (from 17.4 to 22.2 ng/ml) in 4 of 5 patients with chronic active hepatitis. Unlike transaminase activity, which could not discriminate between benign and progressive liver disease, serum levels of procollagen helped in identifying patients with unresolved hepatitis, who were developing chronic active disease.

Original languageEnglish
Pages (from-to)37-44
Number of pages8
JournalLa Ricerca in Clinica e in Laboratorio
Issue number1
Publication statusPublished - Jan 1988


  • Acute viral hepatitis
  • Chronic active hepatitis
  • Hepatic fibrosis
  • Procollagen type III peptide
  • Radioimmunoassay

ASJC Scopus subject areas

  • Clinical Biochemistry


Dive into the research topics of 'Serum procollagen type III peptide levels in patients with acute viral hepatitis'. Together they form a unique fingerprint.

Cite this